UBS Group’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-27,900
Closed -$1.93M – 9740
2023
Q2
$1.93M Hold
27,900
– – ﹤0.01% 3559
2023
Q1
$1.35M Buy
+27,900
New +$1.36M ﹤0.01% 3829

Other funds holding LEGN

UBS Group's LEGN Position: Q3 2026 in Review

UBS Group increased its Legend Biotech (LEGN) stake by 8% in Q3 2026, buying an estimated $853K and bringing the position to 542,465 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3323.

UBS Group first reported a position in LEGN in Q2 2020 and has held it in 26 quarters since. The position peaked at $36.3M in Q2 2025. 198 funds tracked by Wall St. Rank hold LEGN as of Q3 2026.

  • UBS Group held 542,465 shares of Legend Biotech worth $10.8M as of Q3 2026.
  • UBS Group bought 39,999 Legend Biotech shares in Q3 2026, an estimated $853K.
  • Legend Biotech made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #3323 holding.
  • UBS Group first reported a position in Legend Biotech in Q2 2020 and has held it in 26 quarters since.
  • UBS Group's Legend Biotech position peaked at $36.3M in Q2 2025.
  • 198 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.